Trending Stocks

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Comm...

July 17, 2026 07:30:00 am | GlobeNewswire

Triller Group Inc. Addresses Recent Stock Price Volatility

Los Angeles, July 17, 2026 (GLOBE NEWSWIRE) -- Triller Group Inc. (Nasdaq: ILLR; ILLRW) (“Triller” or the “Company”) issued a statement in response to recent volatility in its common stock price, which declined more than 45% to close at $1.28 per share on July 15, 2026...

July 17, 2026 09:00:00 am | GlobeNewswire

Kartoon Studios Advances IP-Focused Strategy with Sale of Frederator Channel Network Business

Company Retains Key Frederator Studios IP For Licensing Opportunities Strategic Transaction Continues Company’s Realignment Towards the Monetization of Premium Intellectual Property BEVERLY HILLS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Kartoon Studios, Inc. (NYSE American: T...

July 17, 2026 09:00:00 am | GlobeNewswire

Wakefern and ShopRite Expand Edible Garden's Successful "Garden Starters" Program with Midsummer Promotion

BELVIDERE, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW),  a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce, and developer of the ...

July 17, 2026 07:41:00 am | GlobeNewswire

Ridgepost Capital to Announce Second Quarter 2026 Financial Results and Host Investor Call

DALLAS, July 17, 2026 (GLOBE NEWSWIRE) -- Ridgepost Capital, Inc. (NYSE: RPC) (“Ridgepost Capital” or the “Company”), a leading private markets solutions provider, today announced it will release financial results for the second quarter 2026 before the market open on...

July 17, 2026 07:00:00 am | GlobeNewswire

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA33890 1 , a TGFβR2×PD-1 bispecific antibody, are being eval...

July 17, 2026 01:10:00 pm | Business Wire